- Home
- WGRX vs ARMP Comparison
WGRX vs ARMP Comparison
Compare WGRX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- ARMP
- Stock Information
- Founded
- WGRX 2022
- ARMP N/A
- Country
- WGRX United States
- ARMP United States
- Employees
- WGRX N/A
- ARMP N/A
- Industry
- WGRX Other Pharmaceuticals
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WGRX Health Care
- ARMP Health Care
- Exchange
- WGRX Nasdaq
- ARMP Nasdaq
- Market Cap
- WGRX 111.0M
- ARMP 104.3M
- IPO Year
- WGRX 2025
- ARMP N/A
- Fundamental
- Price
- WGRX $0.68
- ARMP $3.12
- Analyst Decision
- WGRX
- ARMP Strong Buy
- Analyst Count
- WGRX 0
- ARMP 1
- Target Price
- WGRX N/A
- ARMP $9.00
- AVG Volume (30 Days)
- WGRX 1.3M
- ARMP 7.8K
- Earning Date
- WGRX 11-11-2025
- ARMP 11-12-2025
- Dividend Yield
- WGRX N/A
- ARMP N/A
- EPS Growth
- WGRX N/A
- ARMP N/A
- EPS
- WGRX N/A
- ARMP N/A
- Revenue
- WGRX $36,738,599.00
- ARMP $6,868,000.00
- Revenue This Year
- WGRX N/A
- ARMP $8.43
- Revenue Next Year
- WGRX N/A
- ARMP N/A
- P/E Ratio
- WGRX N/A
- ARMP N/A
- Revenue Growth
- WGRX 82384.51
- ARMP 84.67
- 52 Week Low
- WGRX $0.62
- ARMP $0.90
- 52 Week High
- WGRX $7.04
- ARMP $3.14
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- ARMP 62.83
- Support Level
- WGRX N/A
- ARMP $2.94
- Resistance Level
- WGRX N/A
- ARMP $3.07
- Average True Range (ATR)
- WGRX 0.00
- ARMP 0.08
- MACD
- WGRX 0.00
- ARMP -0.01
- Stochastic Oscillator
- WGRX 0.00
- ARMP 97.96
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.